Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CCND3
REST API REST API
Homo sapiens
CCND3 is differentially expressed in 341 experiments: 87 organism parts: lung, thymus, ... (85 more);, 192 disease states: normal, Huntington's disease, ... (190 more);, 95 cell types 339 cell lines 117 compound treatments and 62 other conditions.
Orthologs Ccnd3 (Mus musculus)   Q5ZKI9_CHICK (Gallus gallus)   F1MV86_BOVIN (Bos taurus)   F6S8K9_CIOIN (Ciona intestinalis)   CycD (Drosophila melanogaster)   CCND3 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cyclin-dependent protein kinase activity, cell division, protein binding, cytoplasm, membrane, regulation of cyclin-dependent protein kinase activity, cell cycle, regulation of cell cycle, protein kinase binding, nucleus, signal transduction, T cell proliferation, positive regulation of cyclin-dependent protein kinase activity, cyclin-dependent protein kinase holoenzyme complex, protein phosphorylation, positive regulation of protein phosphorylation
InterPro Term Cyclin-like, Cyclin, C-terminal, Cyclin, N-terminal, Cyclin A/B/D/E
UniProt Accession P30281, D6RDF8, D6RDL3, D6RIX2, D6RI00, Q5T8J1, B3KQ22, E9PB36, E9PAS4
Search EB-eye ENSG00000112576
Show more properties
Experimental Factors
organism part

studied in E-GEOD-803, E-GEOD-6573, E-GEOD-30573, E-GEOD-17539, E-GEOD-17032, ... (31 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

cell line

studied in E-GEOD-17482, E-GEOD-18005, E-GEOD-19397, E-GEOD-2450, E-GEOD-14519, ... (44 experiments)

Factor Value U/D Experiments
A549
3
E-GEOD-36176, E-MTAB-62, E-GEOD-3202
K562
3
E-MTAB-62, E-MTAB-37, E-GEOD-24147
MCF 10A
3
E-GEOD-14990, E-TABM-420, E-GEOD-10890
HL-60
1
3
E-GEOD-5258, E-GEOD-24147, E-GEOD-995, E-MTAB-62
MDAMB231
1
3
E-GEOD-10890, E-TABM-420, E-MTAB-62, E-GEOD-7307
BeWo
2
E-MTAB-37, E-MTAB-62
333 more value(s).


cell type

studied in E-GEOD-492, E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-GEOD-34309, ... (57 experiments)

Factor Value U/D Experiments
CD4-positive T cell
4
E-GEOD-16190, E-MEXP-1600, E-MTAB-24, E-MTAB-25
monocyte
2
E-MEXP-2019, E-MEXP-583
CD56+ NK cells
2
E-TABM-145, E-AFMX-5
epithelial
2
E-GEOD-9196, E-GEOD-13548
whole blood
2
E-GEOD-3026, E-MTAB-25
T cell
1
2
E-GEOD-16190, E-GEOD-13987, E-GEOD-7307
89 more value(s).


disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-TABM-15, E-GEOD-3678, ... (56 experiments)

Factor Value U/D Experiments
normal
13
16
E-GEOD-18842, E-GEOD-2514, E-TABM-666, E-GEOD-3189, E-GEOD-3307, ... (29 experiments)
acute lymphoblastic leukemia
3
E-GEOD-5824, E-MTAB-62, E-MTAB-37
papillary thyroid carcinoma
2
E-GEOD-3467, E-GEOD-3678
chronic lymphocytic leukemia
2
E-GEOD-2466, E-GEOD-6691
T cell acute lymphoblastic leukemia
2
E-MTAB-62, E-MTAB-37
choriocarcinoma
2
E-MTAB-62, E-MTAB-37
186 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-2742, E-GEOD-6907, E-MTAB-798, E-TABM-782, ... (38 experiments)

Factor Value U/D Experiments
hydroxyurea
2
E-GEOD-6431, E-GEOD-571
epidermal growth factor 1 nanomole
1
E-GEOD-6462
diclofenac 16 micromolar
1
E-MTAB-798
amiodarone 0.28 micromolar
1
E-MTAB-798
azathioprine 2.9 micromolar
1
E-MTAB-798
all-trans retinoic acid
1
E-GEOD-995
111 more value(s).


RNAi

studied in E-MEXP-2115, E-MEXP-2759, E-GEOD-1703, E-GEOD-12438, E-MEXP-1509, ... (9 experiments)

Factor Value U/D Experiments
RENT1 knockdown
1
E-GEOD-1703
IMP(1,3)A
1
E-MEXP-548
shZBTB4
1
E-MEXP-1509
non-specific siRNA control
1
E-MEXP-2115
non-targeting�control siRNA
1
E-MEXP-2759
APE1 RNAi
1
E-MEXP-1315
12 more value(s).


alive at endpoint
studied in E-GEOD-4922

biosource provider
studied in E-MTAB-37, E-GEOD-19466, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cell treatment
studied in E-MEXP-1192

cellular component
studied in E-GEOD-1400

clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (12 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-1140, E-GEOD-12172, E-MEXP-1251, ... (11 experiments)

clinical treatment
studied in E-GEOD-6532

developmental stage
studied in E-GEOD-5999, E-MEXP-2359, E-GEOD-2666, E-GEOD-18290, E-GEOD-22601, ... (7 experiments)

disease stage
studied in E-GEOD-7463

disease staging
studied in E-GEOD-19804, E-GEOD-1323, E-GEOD-19743, E-TABM-147, E-GEOD-6764, ... (9 experiments)

double amplification
studied in E-GEOD-22601

environmental stress
studied in E-GEOD-1518, E-GEOD-3720

estrogen receptor status
studied in E-GEOD-6532, E-GEOD-4922

family relationship
studied in E-MEXP-1425

genetic modification
studied in E-MTAB-73, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, E-MEXP-2340, ... (6 experiments)

genotype
studied in E-GEOD-13911, E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, E-TABM-601, ... (13 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

growth condition
studied in E-GEOD-5681, E-MEXP-2657, E-GEOD-20540, E-TABM-440, E-GEOD-837, ... (14 experiments)

histology
studied in E-TABM-234, E-GEOD-9489, E-GEOD-10780

immunoprecipitated protein
studied in E-GEOD-21918

individual
studied in E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-GEOD-16363, E-GEOD-3846, ... (29 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-13637, E-GEOD-12108, E-GEOD-12254, E-GEOD-20948, ... (8 experiments)

injury
studied in E-GEOD-19743

irradiate
studied in E-GEOD-2742

karyotype
studied in E-GEOD-22056

labeling
studied in E-LGCL-5

material type
studied in E-MEXP-455, E-GEOD-15240

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

metastasis
studied in E-GEOD-18105

molecular subtype
studied in E-GEOD-21653

organism
studied in E-AFMX-1, E-GEOD-426

organism status
studied in E-GEOD-19188

p53 ihc
studied in E-GEOD-21653

phenotype
studied in E-GEOD-22152, E-GEOD-22309, E-GEOD-21750, E-GEOD-1460, E-GEOD-5824, ... (7 experiments)

population
studied in E-GEOD-4922

progesterone receptor status
studied in E-GEOD-6532

protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19249, E-GEOD-19246

replicate
studied in E-GEOD-10896

sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-MTAB-798, E-MEXP-70

sbr grade
studied in E-GEOD-21653

sex
studied in E-GEOD-1643, E-GEOD-2466, E-TABM-702, E-GEOD-7307

stimulus
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-22103

subtype
studied in E-GEOD-24283

survival time
studied in E-GEOD-19188

test result
studied in E-GEOD-1926

transfection
studied in E-GEOD-14680

treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-34055, E-GEOD-32685, E-GEOD-34635, ... (11 experiments)

tumor grading
studied in E-GEOD-14359, E-GEOD-4922

weight of protein recovered
studied in E-GEOD-21918

Processing time: 0.934 secs.
 
Gene Expression Atlas 2.0.13- 4/23/12 11:55:46 AM